Neuroscience Sample Clauses

Neuroscience. St. Mary’s College of Maryland (SMCM) welcomes students from College of Southern Maryland into our community of learners. This Articulation Agreement is designed to facilitate College of Southern Maryland students' ease of transfer from the Mathematics and Sciences: General Concentration program at College of Southern Maryland to the SMCM Neuroscience program. This Agreement augments any Guaranteed and Dual Admission agreements signed between The College of Southern Maryland and SMCM. Under this Agreement, College of Southern Maryland students graduating with an Associate of Science (A.S.) in Mathematics and Sciences: General Concentration will be eligible for admission into SMCM Neuroscience program, provided that students:

Neuroscience. WP7: Non-invasive phenotyping of animal models for neurodegenarative diseases - WP8: with the following Sub-Workpackages - WP8.1: Identification of novel neuro-imaging targets in neurodegenarative diseases - WP8.2: Early diagnosis of neurodegenarative diseases - WP9: Neuroinflammation - WP10: Stem cell trafficking in the CNS TOPIC 2.2 Cardiovascular - WP11: with the following Sub-Workpackages - WP11.1: Multimodality characterization of atherosclerotic plaques - WP11.2: Characterization of myocardial angiogenesis - WP12: Cardiac stem cell therapy monitored by Molecular Imaging TOPIC 2.3 Inflammation & Regeneration - WP13: Molecular Imaging of NF-κB activation and imaging chronic inflammation using optical probes The composition of the Workpackages for research activities and their respective leaders are listed in Appendix 4. - Two (2) Workpackages for Dissemination and Spreading of Activities: - WP15.1: Activities of the Board of Training (BOT) - WP15.2: Activities of the Board of Dissemination and Communication (BODIC) Activities to spread excellence will be managed by the Board of Training (BOT), the Board of Dissemination and Communication (BODIC) and the Board for Knowledge and IPR Management (BOKIM), chaired by the Administrator for Knowledge Management (AKM). - One (1) Workpackage for Management Activities: - WP16: Management Activities Modification of Workpackage Any modification to the Workpackage’s representation shall be decided by the SMB which shall then appoint a new representation from amongst the Contractors involved in the relevant Workpackage, on the basis of proposition(s) made by the relevant Workpackage’ members by written way. Such a modification shall be considered as accepted by the Contractors involved in the relevant Workpackage if within fifteen (15) calendar days from receipt thereof, none of them has objected in writing to the Coordinator. Any objection to such a modification shall be submitted for determination to the Governing Board.

Neuroscience. Timing Major Milestones with respect to expected results, achievements, deliverables Start of Program • Establishment of in- and exclusion criteria for all patient groups • Specification of ethical aspects with particular emphasis on patients with degenerative brain disorders and dementia and national regulations • Specification of ethical aspects in animal models with particular emphasis on national regulations • Specification on animal mobility amongst the different partners to allow consecutive multimodal imaging Year 1 • Phenotyping of rat models for Xxxxxxxxx and Huntington Disease • Phenotyping of mice models for Amyotrophic Lateral Sclerosis • Establishment of [11C](R)-PK11195 in other DiMI laboratories • Implementation of protocols for MR-imaging • BBB, microglial probes or tPA probes validated • Establishment of the ability of tPA and tPAstop-tPA complexes to cross the blood-brain barrier and tissue distribution • Initial in-vivo studies in models of cerebral ischemia • Biochemical inflammatory markers, gene expression, and proteomics in patients • Annual implementation plan for Year 2 Year 2 • Phenotyping of primate models for Xxxxxxxxx and Huntington Disease • Implementation of animal brain atlases for automatic VOI definitions • Initial histopathological validation of current neuroimaging markers of inflammation • Initial blood-brain barrier integrity studies in patients with multiple sclerosis • Cross-sectional MR and/or PET in patients with MS, parkinsonism, memory dysfunction, HD, and prion disease • Paramagnetically labeled tPA made available to other partners • Biochemical inflammatory markers, gene expression, and proteomics in patients • Annual implementation plan for Year 3 Year 3 • Improved multimodality diagnostic tools for Alzheimer Disease mice models • Improved in vivo amyloid detection in Alzheimer Disease models • Implementation of new probes derived from Topic 1.2 in other DiMI-centres • Publication: MR-methodology of Q-space and BBB passage in MS patients • Publication: New tracers for microglia activation: Validation study • Publication: tPA probes validation study • Publication: in-vivo studies in models of cerebral ischemia • Establishment of the ability of tPA and tPAstop-tPA complexes to cross the blood-brain barrier and tissue distribution • Initial in-vivo studies in models of cerebral ischemia • Biochemical inflammatory markers, gene expression, and proteomics in patients • Annual implementation plan for Year 4 Year 4 •...

Neuroscience. (a) For each Neuroscience Phenomap, following completion of the applicable Stage 0 Plan, including selection of the Cell Context, the applicable JTT will finalize the Other Map Perturbations to be included in such Neuroscience Phenomap (and, if necessary, amend the applicable Research Plan to include such Other Map Perturbations) and, following agreement on the Phenomap Standards, Recursion will create a [***] Neuroscience Phenomap in such Cell Context, in accordance with such Research Plan; provided that, at Roche’s request, Recursion will not create a [***] Phenomap for such Cell Context (and the Stage 0-1 Activities solely applicable to such [***] Phenomap will be deemed discontinued) and instead will create a [***] Phenomap in such Cell Context as set forth in Section 3.3.2(b).

Neuroscience. (a) Promptly upon Recursion’s completion of each Neuroscience Phenomap, Recursion will provide Roche with written notice of such completion, which shall include data demonstrating achievement of the Phenomap Standards for such Phenomap. During the [***] day period following Roche’s receipt of such notice and data (the “Evaluation Period”), Recursion will permit and facilitate the full access (but not the ability to download) for up to [***] named individuals from, and nominated by, Roche to such Neuroscience Phenomap and the Neuro Image Data used to create such Phenomap, including the ability to query such Phenomap, solely to evaluate Roche’s interest in accepting such Phenomap. For clarity, any observations made pursuant to such queries shall be Collaboration Insights, to the extent they satisfy Section 1.32. For clarity, [***] in such Phenomap for purposes of Roche’s access during the applicable Evaluation Period and, to the extent Roche Small Molecules are included in such Phenomap, at least a subset of reference compounds comprising such Roche Small Molecules will be identified. Recursion will retain the right to maintain an Access Log of all queries to such Phenomap made during such Evaluation Period to monitor compliance with the Agreement. If, during the Evaluation Period for a Phenomap, Roche notifies the applicable JTT that it has concerns about the accuracy, functioning or reliability of such Phenomap, the applicable JTT shall promptly meet to discuss and determine how to address such concerns.